Hypertrophic Cardiomyopathy (HCM)
Conditions
Keywords
hypertrophic cardiomyopathy, myocardial contrast echocardiography, microvascular perfusion
Brief summary
The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.
Interventions
DIAGNOSTIC_TESTmyocardial contrast echo
Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.
Sponsors
University of Virginia
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of hypertrophic cardiomyopathy * Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy
Exclusion criteria
* Pregnancy * Lactation * Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson * Serious AE to regadenoson * Hypotension * Serious bradycardia not addressed by pacemaker * Moderate or greater reactive airways disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peak hyperemic perfusion | 3 months | Myocardial contrast echo-derived myocardial blood flow at peak hyperemia (produced by regadenoson) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Resting myocardial perfusion | 3 months | Resting myocardial perfusion by MCE |
Countries
United States
Outcome results
None listed